MGMT methylation:: A marker of response to temozolomide in low-grade gliomas

被引：169

作者：

Everhard, Sibille

Kaloshi, Gentian

Criniere, Emmanuelle

Benouaich-Amiel, Alexandra

Lejeune, Julie

Marie, Yannick

Sanson, Marc

Kujas, Michele

Mokhtari, Karima

Hoang-Xuan, Khe

Delattre, Jean-Yves

Thillet, Joelle

机构：

[1] INSERM, U711, F-75651 Paris 13, France

[2] Univ Paris 06, Fac Med Pitie Salpetriere, Inst Fed Rech 70, F-75651 Paris, France

[3] Hop La Pitie Salpetriere, AP HP, Serv Neurol Mazarin, Paris, France

来源：

ANNALS OF NEUROLOGY | 2006年 / 60卷 / 06期

关键词：

D O I：

10.1002/ana.21044

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

The methylation status of the O6-methylguanine-methyltransferase promoter (MGMTP) was evaluated in 68 low-grade gliomas treated by neoadjuvant temozolomide. Methylated MGMTP was detected in 63 of 68 (92.6 %) patients and was a favorable predictor of progression-free survival as compared with unmethylated MGMTP tumors (p < 0.0001). Assessment of MGMTP status could help identifying low-grade gliomas patients more likely to respond to chemotherapy or to benefit from MGMT depletion strategies.

引用

收藏

页码：740 / 743

页数：4

相关论文

共 17 条

[1] Aberrant promoter methylation of multiple genes in oligodendrogliomas and ependymomas [J].

Alonso, ME ;

Bello, MJ ;

Gonzalez-Gomez, P ;

Arjona, D ;

Lomas, J ;

de Campos, JM ;

Isla, A ;

Sarasa, JL ;

Rey, JA .

CANCER GENETICS AND CYTOGENETICS, 2003, 144 (02) :134-142

[2] Primary brain tumours in adults [J].

Behin, A ;

Hoang-Xuan, K ;

Carpentier, AF ;

Delattre, JY .

LANCET, 2003, 361 (9354) :323-331

[3] Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas [J].

Cairncross, JG ;

Ueki, K ;

Zlatescu, MC ;

Lisle, DK ;

Finkelstein, DM ;

Hammond, RR ;

Silver, JS ;

Stark, PC ;

Macdonald, DR ;

Ino, Y ;

Ramsay, DA ;

Louis, DN .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1998, 90 (19) :1473-1479

[4] Brain tumours: Classification and genes [J].

Collins, VP .

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2004, 75 :2-11

[5] Concurrent hypermethylation of multiple genes is associated with grade of oligodendroglial tumors [J].

Dong, SM ;

Pang, JCS ;

Poon, WS ;

Hu, J ;

To, KF ;

Chang, AR ;

Ng, HK .

JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 2001, 60 (08) :808-816

[6] Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents [J].

Esteller, M ;

Garcia-Foncillas, J ;

Andion, E ;

Goodman, SN ;

Hidalgo, OF ;

Vanaclocha, V ;

Baylin, SB ;

Herman, JG .

NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (19) :1350-1354

[7] Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide [J].

Hegi, ME ;

Diserens, AC ;

Godard, S ;

Dietrich, PY ;

Regli, L ;

Ostermann, S ;

Otten, P ;

Van Melle, G ;

de Tribolet, N ;

Stupp, R .

CLINICAL CANCER RESEARCH, 2004, 10 (06) :1871-1874

[8] MGMT gene silencing and benefit from temozolomide in glioblastoma [J].

Hegi, ME ;

Diserens, A ;

Gorlia, T ;

Hamou, M ;

de Tribolet, N ;

Weller, M ;

Kros, JM ;

Hainfellner, JA ;

Mason, W ;

Mariani, L ;

Bromberg, JEC ;

Hau, P ;

Mirimanoff, RO ;

Cairncross, JG ;

Janzer, RC ;

Stupp, R .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (10) :997-1003

[9] Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions [J].

Hoang-Xuan, K ;

Capelle, L ;

Kujas, M ;

Taillibert, S ;

Duffau, H ;

Lejeune, J ;

Polivka, M ;

Crinière, E ;

Marie, Y ;

Mokhtari, K ;

Carpentier, AF ;

Laigle, F ;

Simon, JM ;

Cornu, P ;

Broët, P ;

Sanson, M ;

Delattre, JY .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (15) :3133-3138

[10]

Komine C, 2003, BRAIN PATHOL, V13, P176